References

Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy

10.1053/j.gastro.2022.10.018 · 2023 · External reference

Interaction between microbiota and immunity in health and disease

10.1038/s41422-020-0332-7 · 2020 · External reference

Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions

10.1016/j.cell.2022.09.005 · 2022 · External reference

A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors

10.1016/j.cell.2022.09.015 · 2022 · External reference

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

10.1126/science.1240537 · 2013 · External reference

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment

10.1126/science.1240527 · 2013 · External reference

Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study

10.1158/1078-0432.ccr-20-3445 · 2021 · External reference

Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma

10.1038/s41467-020-18127-y · 2020 · External reference

Targeting regorafenib-induced toxicity through inhibition of gut microbial β-glucuronidases

10.1021/acschembio.9b00663 · 2019 · External reference

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

10.1126/science.aan4236 · 2018 · External reference

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer

10.1111/1759-7714.15303 · 2024 · External reference

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

10.1038/s41591-022-01694-6 · 2022 · External reference

Gut microbiome and immune checkpoint inhibitor toxicity

10.1016/j.ejca.2025.115221 · 2025 · External reference

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

10.1126/science.aaz7015 · 2021 · External reference

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis

10.3389/fimmu.2023.1070076 · 2023 · External reference

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

10.1126/science.aan3706 · 2018 · External reference

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients

10.1126/science.abf3363 · 2021 · External reference

Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor

10.1016/j.chom.2024.06.010 · 2024 · External reference

Alleviating cancer drug toxicity by inhibiting a bacterial enzyme

10.1126/science.1191175 · 2010 · External reference

Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation

10.1038/s42003-021-01741-x · 2021 · External reference

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer

10.1111/1759-7714.13711 · 2021 · External reference

The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer

10.1002/ctm2.1312 · 2023 · External reference

Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer

10.1002/cncr.35229 · 2024 · External reference

The interplay between gut bacteria and targeted therapies: implications for future cancer treatments

10.1186/s10020-025-01108-6 · 2025 · External reference

Gut microbiota and sunitinib-induced diarrhea in metastatic renal cell carcinoma: a pilot study

10.2147/cmar.s328451 · 2021 · External reference

Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma

10.1159/000524298 · 2023 · External reference

Relationship between adverse events and microbiomes in advanced hepatocellular carcinoma patients treated with sorafenib

10.21873/anticanres.13996 · 2020 · External reference

Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer

2022 · External reference

Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma

10.1038/s41598-025-11054-2 · 2025 · External reference

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

10.1186/s12885-022-10050-3 · 2022 · External reference

The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC

10.1016/j.jtho.2019.04.007 · 2019 · External reference

Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors

10.1016/j.eururo.2020.07.011 · 2020 · External reference

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

10.1126/science.aao3290 · 2018 · External reference

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

10.1038/s41591-021-01655-5 · 2022 · External reference

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

10.1126/science.abc3421 · 2020 · External reference

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

10.1126/science.aac4255 · 2015 · External reference

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

10.1093/annonc/mdy103 · 2018 · External reference

A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors

10.3389/fonc.2023.1075593 · 2023 · External reference

Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America

10.1093/cid/ciw118 · 2016 · External reference

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

10.1038/ncomms10391 · 2016 · External reference

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

10.1093/annonc/mdx108 · 2017 · External reference

The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer

10.1158/2326-6066.cir-20-0196 · 2020 · External reference

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

10.1038/s41591-018-0238-9 · 2018 · External reference

Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis

10.1126/scitranslmed.abq4006 · 2023 · External reference

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

10.1126/science.abb5920 · 2021 · External reference

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

10.1038/s41591-022-01702-9 · 2022 · External reference

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

2022 · External reference

Gut microbiota modulation through Akkermansia spp supplementation increases CAR T-cell potency

10.1158/2159-8290.cd-24-1230 · 2025 · External reference

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

10.1038/s41591-023-02234-6 · 2023 · External reference

Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response

10.1016/j.medj.2024.10.007 · 2025 · External reference

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

10.1038/s41591-023-02453-x · 2023 · External reference

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial

10.1038/s41591-025-04186-5 · 2026 · External reference

Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial

10.1038/s41591-025-04189-2 · 2026 · External reference

Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial

10.1038/s41591-025-04183-8 · 2026 · External reference

Fecal microbiota transplantation in refractory immune-mediated colitis: case series and review of the literature

10.3390/ph18111719 · 2025 · External reference

Early antibiotic use after fecal microbiota transplantation increases risk of treatment failure

10.1093/cid/cix684 · 2018 · External reference

Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation

10.1016/j.chom.2018.01.003 · 2018 · External reference

Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics

10.1038/nrgastro.2017.75 · 2017 · External reference

Association of a mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma

10.1001/jamaoncol.2022.7753 · 2023 · External reference

Prebiotic-induced anti-tumor immunity attenuates tumor growth

10.1016/j.celrep.2020.01.035 · 2020 · External reference

Effect of inulin and fructo-oligosaccharide on the prevention of acute radiation enteritis in patients with gynecological cancer and impact on quality-of-life: a randomized, double-blind, placebo-controlled trial

10.1038/ejcn.2015.192 · 2016 · External reference

Effect of a mixture of inulin and fructo-oligosaccharide on Lactobacillus and Bifidobacterium intestinal microbiota of patients receiving radiotherapy: a randomised, double-blind, placebo-controlled trial

2012 · External reference

Benefaction of probiotics for human health: a review

2018 · External reference

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma

10.1002/cam4.3569 · 2021 · External reference

Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer

10.1002/ijc.34842 · 2024 · External reference

Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial

10.1016/j.ijrobp.2007.11.009 · 2008 · External reference

Randomized double-blind, placebo-controlled multicenter phase 3 study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12 Lactobacillus rhamnosus LGG in colorectal cancer patients

10.3389/fonc.2023.1168654 · 2023 · External reference

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

10.1038/sj.bjc.6603990 · 2007 · External reference

Oral compound probiotic supplements can improve the quality of life for patients with lung cancer during chemotherapy: a randomized placebo-controlled study

10.1111/1759-7714.15177 · 2024 · External reference

The mechanisms and therapeutic potential of the microbiome-immune interface in cancer

10.1007/s44340-025-00031-0 · 2025 · External reference

Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors

10.1007/s10637-025-01573-0 · 2025 · External reference

Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity

10.1158/2159-8290.cd-24-0066 · 2024 · External reference

First-in-class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

10.1016/j.annonc.2023.02.011 · 2023 · External reference

Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naive patients with cancer: updated safety data

2023 · External reference

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

10.1038/s41591-024-03086-4 · 2024 · External reference

Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer

10.1158/2326-6066.cir-20-0051 · 2020 · External reference